Health Care & Life Sciences » Pharmaceuticals | OncoVista Innovative Therapies Inc.

OncoVista Innovative Therapies Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2010
2011
2012
2013
2014
Cost of Goods Sold (COGS) incl. D&A
9.30
6.70
-
3.00
0.50
Gross Income
9.30
6.70
-
3.00
0.50
SG&A Expense
2,389.20
2,194.40
1,974.50
1,519.20
2,545.30
EBIT
2,398.50
2,201.20
1,981.30
1,522.20
2,545.80
Unusual Expense
265.30
21.40
355.10
72.50
9.70
Non Operating Income/Expense
9.70
10.00
0.90
-
-
Interest Expense
147.00
24.10
6.80
0.20
8.30
Pretax Income
2,289.90
2,229.60
1,628.80
1,449.60
2,544.40
Consolidated Net Income
2,289.90
2,229.60
1,628.80
1,449.60
2,544.40
Net Income
2,289.90
2,229.60
1,628.80
1,449.60
2,544.40
Net Income After Extraordinaries
14,683.20
2,434.10
1,628.80
1,449.60
2,544.40
Net Income Available to Common
2,562.10
2,229.60
1,628.80
1,449.60
2,544.40
EPS (Basic)
0.49
0.10
0.08
0.07
0.12
Basic Shares Outstanding
20,483.00
21,309.80
21,511.90
21,627.90
21,651.10
EPS (Diluted)
0.49
0.10
0.08
0.07
0.12
Diluted Shares Outstanding
20,483.00
21,309.80
21,511.90
21,627.90
21,651.10
EBITDA
2,389.20
2,194.40
1,974.50
1,519.20
2,545.30
Non-Operating Interest Income
-
7.00
3.40
0.30
-

About OncoVista Innovative Therapies

View Profile
Address
14785 Omicron Drive
San Antonio Texas 78245
United States
Employees -
Website -
Updated 07/08/2019
OncoVista Innovative Therapies, Inc. is a drug development company, which engages in the development and commercialization of targeted cancer therapies. The company produces drug discovery, registration strategies, and emerging technologies. Its products include Cordycepin and L-Nucleoside Conjugate.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.